Literature DB >> 2369738

Comparison of the predictive power of different prognostic indices for overall survival in patients with advanced ovarian carcinoma.

B Lund1, P Williamson, H C van Houwelingen, J P Neijt.   

Abstract

Validation of a 5-covariate prognostic index (PI5) (performance status, stage, residual tumor size, histological grade, and ascites) derived from a group of 268 Dutch patients with advanced ovarian carcinoma was performed in a similar study of 301 Danish patients. Analysis of survival suggested an alternative 4-covariate PI (performance status, residual tumor size, age, weight/body surface) for the latter group. As residual tumor size and performance status were common to both indices, the predictive power of this 2-covariate PI (PI2) was also assessed in the Danish study and, subsequently, validated in the Dutch patients. The PI5 defined 10 and 9% of the Dutch patients as low and high risk patients with 3-year survival rates of 80 and 8%, respectively. In the Danish study the PI5 classified 14% to be high risk patients with a 3-year survival rate of 18%. Only a few patients (3%) were classified as low risk, making comparisons irrelevant. The PI2 classified 33 and 26% of the Danish patients as having 3-year survival rates of 67 and 13%, respectively. The corresponding Dutch PI2 values were 41 and 15% of the patients with 3-year survival rates of 60 and 8%, respectively. Although the PI5 possessed a better validity in the Danish study than the PI2 in the Dutch study, the PI2 may be the best prognostic index available for general use.

Entities:  

Mesh:

Year:  1990        PMID: 2369738

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Value of quantitative pathological variables as prognostic factors in advanced ovarian carcinoma.

Authors:  M Brinkhuis; J P Baak; G A Meijer; P J van Diest; O Mogensen; P Bichel; J P Neijt
Journal:  J Clin Pathol       Date:  1996-02       Impact factor: 3.411

2.  Does Aquaporin-1 expression have clinical significance in serous epithelial ovarian cancer?

Authors:  Mustafa Kemal Takal; Cem Baykal; Eralp Başer; Mustafa Derda Kaya; Polat Dursun; Ozlem Ozen; Asuman Nihan Haberal; Ali Ayhan
Journal:  J Turk Ger Gynecol Assoc       Date:  2013-09-01

3.  Performance status assessment in cancer patients. An inter-observer variability study.

Authors:  J B Sørensen; M Klee; T Palshof; H H Hansen
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

4.  A prognostic model for ovarian cancer.

Authors:  T G Clark; M E Stewart; D G Altman; H Gabra; J F Smyth
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

5.  Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer.

Authors:  M Ando; Y Ando; Y Hasegawa; K Shimokata; H Minami; K Wakai; Y Ohno; S Sakai
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

6.  Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma.

Authors:  D M Eccles; L Brett; A Lessells; L Gruber; D Lane; C M Steel; R C Leonard
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.